AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, orally once per day for 8 weeks
Study NCT02575885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02575885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02575885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01284465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and patient liaison combination
Description: Group education sessions with Patient liaison using ecological momentary assessment principles
Study NCT01284465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Group education sessions at baseline, 3 and 6 months
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost
Description: Lower intraocular pressure by increasing outflow of fluid from the eye.
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Lower intraocular pressure by decreasing production of fluid
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study NCT02390284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: Lowers intraocular pressure by decreasing intraocular fluid production
Study NCT06692517 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline/[S,S]-reboxetine
Description: Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks
Study NCT00636246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [S,S]-reboxetine monotherapy
Description: Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
Study NCT02400918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)
Description: An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
Study NCT04433182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year
Study NCT01955720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01827800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth weight loss intervention
Description: This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
Study NCT02261519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaBen®
Description: 500 mg twice daily (1000 mg total)
Study NCT02261519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg twice daily (0 mg total)
Study NCT02251405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One bag, stainless container
Study NCT02251405 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: One bag, stainless container
Study NCT04138537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OB volume
Description: The mean OB volume was calculated in cubic millimeters and compared between the two groups.
Study NCT01103141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Micropuncture needle set
Description: Groin access for vascular intervention
Study NCT01103141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard gauge-18 needle set
Description: Groin access for vascular intervention
Study NCT04194541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed Sorbact Hydroactive B wound dressing
Description: Wound dressing applied and changed as needed.
Study NCT04138537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CCCRC test
Description: CCCRC test was done for olfactory function assessment and compared between the two groups.
Study NCT03225209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIFAST
Description: OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
Study NCT00150488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uracyst
Description: 2% weekly for 6 weeks, monthly for 4 months
Study NCT04404764 — intervention group
Intervention type: DRUG
Intervention: Nusinersen Injectable Product
Description: The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
Study NCT02390921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisiogen Ferro Forte
Description: The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
Study NCT02390921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
Study NCT03187418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroPulse® P3 Glaucoma Device (MP3)
Description: Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s).
Study NCT03177460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03177460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMS Inhibitor JNJ-40346527
Description: Given PO
Study NCT03177460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT02407925 — intervention group
Intervention type: BEHAVIORAL
Intervention: Feedback
Description: 3-monthly or no 3-monthly feedback on results of optical diagnosis
Study NCT00083759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natalizumab
Study NCT00083759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00600912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid®
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
Study NCT00600912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-ClinOleic 20%®
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
Study NCT03260829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin C
Description: 25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
Study NCT03260829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: 25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
Study NCT06273514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECAR
Description: TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM.
Study NCT06273514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe.
Study NCT02028767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 2.5 mg
Description: Empagliflozin 2.5 mg tablet
Study NCT02028767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Empagliflozin 10 mg tablet
Study NCT02028767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet
Study NCT02028767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin FDC
Description: 12.5 mg Empagliflozin / 500 mg Metformin
Study NCT03445741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised treadmill group (%70 VO2 max) (group 1)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
Study NCT03445741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised treadmill group (%50 VO2 max) (group 2)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study NCT03445741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECE PEDO pedometer group (%50 VO2 max) (group 3)
Description: Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study NCT03205722 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03806933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
Study NCT01886209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT01886209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Study NCT01886209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00674960 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT03855527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
Study NCT03855527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
Study NCT03855527 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Atraumatic Restorative Treatment without Disinfection
Description: Atraumatic Restorative Technique will be performed without cavity disinfection
Study NCT01906853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Study NCT04194541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutimed Siltect wound dressing
Description: Wound dressing applied and changed as needed.
Study NCT04194541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sorbion Sana multi-star wound dressing
Description: Wound dressing applied and changed as needed.
Study NCT02411253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-2
Description: Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
Study NCT02411253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
Study NCT03263104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum ECGC 13110402
Description: Lactobacillus plantarum ECGC 13110402
Study NCT03263104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT00840918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
Study NCT00840918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
Study NCT02618109 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples
Study NCT04057937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast
Study NCT04057937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT05264311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Description: The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP.
Study NCT02394171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Cohesion
Description: See description in arm/group above
Study NCT02394171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cohesion
Description: See description in arm/group above
Study NCT01973179 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy
Description: Radiation therapy with protons
Study NCT01938209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seated thoracic manipulation
Description: seated general thoracic spine manipulation
Study NCT01938209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine specific thoracic spine manipulation
Description: supine specific thoracic spine manipulation
Study NCT04562571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charter & patient information leaflets
Description: Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
Study NCT02771184 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Sound Recording System
Description: The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
Study NCT02357355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UIHC Driving Simulator
Description: This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
Study NCT00098514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talotrexin ammonium
Study NCT04425564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronomic XELOX
Study NCT04425564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic XELOX